Loading...
XHKG
6622
Market cap203mUSD
Jul 17, Last price  
2.93HKD
1D
4.64%
1Q
95.33%
IPO
-76.56%
Name

Zhaoke Ophthalmology Ltd

Chart & Performance

D1W1MN
P/E
P/S
21.13
EPS
Div Yield, %
Shrs. gr., 5y
0.41%
Rev. gr., 5y
%
Revenues
69m
+269.73%
0000018,750,00069,324,000
Net income
-237m
L-38.32%
-36,881,000-123,660,000-728,636,000-2,134,215,000-410,459,000-385,038,000-237,493,000
CFO
0k
P
22,082,000-55,212,000-103,425,000-245,143,000-331,050,000-323,664,0000

Profile

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that cover ophthalmic indications affecting the anterior and posterior segments, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.
IPO date
Apr 29, 2021
Employees
321
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
69,324
269.73%
18,750
 
Cost of revenue
355,511
380,713
344,520
Unusual Expense (Income)
NOPBT
(286,187)
(361,963)
(344,520)
NOPBT Margin
Operating Taxes
550
3,142
Tax Rate
NOPAT
(286,187)
(362,513)
(347,662)
Net income
(237,493)
-38.32%
(385,038)
-6.19%
(410,459)
-80.77%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,853
1,250
BB yield
-0.09%
-0.08%
Debt
Debt current
222,538
216,162
104,225
Long-term debt
42,031
53,313
65,131
Deferred revenue
13,705
7
Other long-term liabilities
14,340
7
Net debt
(926,592)
(1,192,148)
(1,555,868)
Cash flow
Cash from operating activities
(323,664)
(331,050)
CAPEX
(36,467)
(238,552)
Cash from investing activities
(75,768)
(324,568)
Cash from financing activities
99,294
76,230
FCF
(363,999)
(389,617)
(533,993)
Balance
Cash
1,191,161
1,461,623
1,725,224
Long term investments
Excess cash
1,187,695
1,460,686
1,725,224
Stockholders' equity
1,900,077
(3,806,856)
(3,079,138)
Invested Capital
965,309
6,106,905
5,558,250
ROIC
ROCE
EV
Common stock shares outstanding
546,139
543,923
542,173
Price
1.20
-69.62%
3.95
30.79%
3.02
-46.83%
Market cap
655,367
-69.50%
2,148,495
31.22%
1,637,362
-30.10%
EV
(271,225)
956,347
81,494
EBITDA
(286,187)
(313,259)
(309,446)
EV/EBITDA
0.95
Interest
7,921
3,142
Interest/NOPBT